Dark

Check out our Dark Pool Levels

PTN
Palatin Technologies, Inc.
stock NYSEAMERICAN

Inactive

May 23, 2025

65.83USD+69857.492%(+65.74)1,400

Pre-market

0.00USD-100.000%(-0.09)0

After-hours

0.00USD0.000%(0.00)0

OverviewOptionsHistoricalExchangesShortsNews

Jan 21, 2022

07:47AM EST Palatin: Pre-clinical Data Show Positive Effects Of RTTNews

07:32AM EST Palatin Announces Presentation Of Positive Effects Of PL8177 On Treating Ulcerative Colitis In Animal Disease Model RTTNews

07:31AM EST Palatin Announces Presentation at the 2022 Crohn's and Colitis Congress PR Newswire

Jan 7, 2022

11:00AM EST Palatin to Present at H.C. Wainwright BioConnect Conference PR Newswire

Dec 28, 2021

08:13AM EST Palatin Technologies Inc. (PTN) said on Tuesday that it has initiated a pivotal phase III clinical study of PL9643, an ophthalmic solution, in patients with dry eye disease. RTTNews

07:32AM EST Palatin Begins Pivotal Phase 3 PL9643 MELODY-1 Clinical Trial In Patients With Dry Eye Disease RTTNews

07:30AM EST Palatin Announces Initiation of Pivotal Phase 3 PL9643 MELODY-1 Clinical Trial PR Newswire

07:30AM EST Palatin Announces Initiation Of Pivotal Phase 3 PL9643 MELODY-1 Clinical Trial In Patients With Dry Eye Disease Benzinga

Dec 2, 2021

08:55AM EST Watching Shares Of Palatin Technologies; Traders Circulate Seeking Alpha Blog Post From Contributor Biotechlab's Blog Titled 'COVID-19 PLAY: $PTN (Palatin Technologies, Inc.) To Develop PL8177 As A Potential Treatment For COVID-19 And Associated Lung Complications...' Benzinga

Nov 30, 2021

07:31AM EST Notice of Allowance Issued for Method of Treating Cytokine Storm Using PR Newswire

Nov 26, 2021

11:23AM EST Watching Shares Of Palatin Technologies; Traders Circulate Seeking Alpha Post From Biotechlab's Blog Titled 'COVID-19 PLAY: $PTN (Palatin Technologies, Inc.) To Develop PL8177 As A Potential Treatment For COVID-19 And Associated Lung Complications...' Benzinga

Nov 24, 2021

07:37AM EST 10 Biggest Price Target Changes For Wednesday Benzinga

06:08AM EST HC Wainwright & Co. Maintains Buy on Palatin Technologies, Raises Price Target to $5 Benzinga

Nov 15, 2021

11:53AM EST Looking Into Palatin Technologies's Return On Capital Employed Benzinga

11:07AM EST Earnings Scheduled For November 15, 2021 Benzinga

11:02AM EST Palatin Technologies Q1 EPS $(0.03), Inline, Sales $159.48K Beat $80.00K Estimate Benzinga

07:34AM EST Palatin Q1 Net Loss $7.1 Mln Or $0.03/Shr Vs Loss Of $3.9 Mln Or $0.02/Shr Last Year RTTNews

07:31AM EST Palatin Reports First Quarter Fiscal Year 2022 Results and Provides Corporate PR Newswire

Nov 10, 2021

04:31PM EST Palatin to Report First Quarter, Fiscal Year 2022 Results; Teleconference and PR Newswire

Oct 22, 2021

07:31AM EDT Palatin Awarded "Top 10 Poster" Designation at the American Society of Retina PR Newswire

Oct 6, 2021

11:48AM EDT Palatin Technologies's Return On Capital Employed Overview Benzinga

Sep 29, 2021

07:59AM EDT Palatin Posts Wider Loss In Q4 - Quick Facts RTTNews

07:42AM EDT Palatin Technologies Q4 EPS $(0.06) Misses $(0.03) Estimate, Sales $175.19K Miss $870.00K Estimate Benzinga

07:34AM EDT Palatin Q4 Net Loss $13.9 Mln Or $0.06/Shr Vs Loss $7.3 Mln Or $0.03/Shr Last Year RTTNews

07:31AM EDT Palatin Reports Fourth Quarter and Full Year Fiscal Year 2021 Financial Results PR Newswire

03:33AM EDT Earnings Scheduled For September 29, 2021 Benzinga

Sep 27, 2021

07:32AM EDT Palatin To Present On Protective Effects Of PL8331 And PL9654 On Retinal Inflammation At 2021 American Society Of Retina Specialists Annual Meeting Oct. 8-12 Benzinga

07:32AM EDT Palatin Presents Positive Protective Effects Of PL8331 And PL9654 On Retinal Inflammation At ASRS RTTNews

07:31AM EDT PL9654 on Retinal Inflammation at the 2021 American Society of Retina Specialists (ASRS) Annual Meeting PR Newswire

Sep 24, 2021

07:30AM EDT Palatin To Report Fourth Quarter And Fiscal Year End 2021 Results; PR Newswire

Sep 15, 2021

07:31AM EDT Palatin to Present Peptides Platform at the TIDES USA Conference PR Newswire

Sep 13, 2021

07:01AM EDT Palatin to Participate in H.C. Wainwright 23rd Annual Global Investment Virtual PR Newswire

Jul 22, 2021

05:29PM EDT Palatin Announces Presentation at the Eyecelerator@ASCRS Conference PR Newswire

Jul 8, 2021

04:16PM EDT Palatin Announces Adjournment of Annual Meeting of Stockholders PR Newswire

Jun 29, 2021

09:18AM EDT Palatin Technologies Stock Moves Higher After Outlining Plans For Dry Eye Disease Treatment Benzinga

07:34AM EDT Palatin Announces Positive End-of-Phase 2 Meeting With FDA On PL9643 For Dry Eye Disease RTTNews

07:31AM EDT Palatin Announces Completion Of End-Of-Phase 2 Meeting With FDA On PL9643 For Dry Eye Disease; Co. And FDA Reached Agreement On All Ket Elements Of Phase 3 Program Benzinga

07:31AM EDT Palatin Announces Positive End-of-Phase 2 Meeting with FDA on PL9643 for the PR Newswire

Jun 28, 2021

07:32AM EDT Palatin Technologies Appoints Michael Raizman As Chief Medical Officer RTTNews

07:31AM EDT Palatin Announces New Additions to Its Senior Leadership Team PR Newswire

Jun 10, 2021

07:30AM EDT Palatin Announces Adjournment of Annual Meeting of Stockholders PR Newswire

May 17, 2021

01:33PM EDT Return On Capital Employed Overview: Palatin Technologies Benzinga

07:40AM EDT Palatin Technologies Q3 EPS $(0.02) Beats $(0.04) Estimate, Sales $88.74K Miss $1.28M Estimate Benzinga

07:34AM EDT Palatin Posts Q3 Revenues Of $88.74 Mln RTTNews

07:34AM EDT Palatin Q3 Net Loss $5.7 Mln Or $0.02/Shr Vs Loss Of $5.4 Mln Or $0.02/Shr Last Year RTTNews

07:31AM EDT Palatin Reports Financial Results for the Third Fiscal Quarter of 2021 and PR Newswire

04:10AM EDT Earnings Scheduled For May 17, 2021 Benzinga

May 14, 2021

07:31AM EDT Palatin Hosting Key Opinion Leader Webinar in Role of Melanocortin Agonists in PR Newswire

May 13, 2021

07:31AM EDT Palatin to Report Third Quarter, Fiscal Year 2021 Results; Teleconference and PR Newswire

May 6, 2021

07:49AM EDT The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom Benzinga

May 4, 2021

07:49AM EDT Palatin Announces U.S. Patent Term Extension For Vyleesi To Jun. 25, 2025 Benzinga

07:31AM EDT Palatin Announces U.S. Patent Term Extension for Vyleesi(r) (bremelanotide PR Newswire

Apr 20, 2021

07:38AM EDT Palatin Announces Two Presentations At 2021 Association For Research In Vision And Ophthalmology (ARVO) Annual Meeting May 1-7 Benzinga

07:31AM EDT Palatin Announces Two Presentations at the 2021 Association for Research in PR Newswire

Mar 5, 2021

07:31AM EST Palatin Technologies to Participate in H.C. Wainwright Global Life Sciences PR Newswire

Feb 17, 2021

07:33AM EST Palatin Technologies Q2 Net Loss $10.0 Mln Or $0.04/Shr Vs Loss Of $5.2 Mln Or $0.02/Shr Last Year RTTNews

07:31AM EST Palatin Technologies Q2 EPS $(0.04) Misses $(0.01) Estimate Benzinga

07:30AM EST Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2021 Financial PR Newswire

04:34AM EST Earnings Scheduled For February 17, 2021 Benzinga

Feb 12, 2021

07:30AM EST Palatin Technologies, Inc. to Report Second Quarter, Fiscal Year 2021 Results; PR Newswire

Feb 10, 2021

08:01AM EST Palatin Shares Spikes On International Patent Application Covering Its Dry Eye Disease Candidate Benzinga

07:33AM EST Palatin Tech Announces Filing Of International Patent Application Claiming PL9643 RTTNews

07:33AM EST Palatin Technologies Announces Filing Of International Patent Application Claiming PL9643 Benzinga

07:31AM EST Palatin Technologies Announces Filing of International Patent Application PR Newswire

Dec 15, 2020

07:21AM EST Biopharmaceutical company Palatin Technologies, Inc. (PTN) on Tuesday announced positive results in its Phase 2 study of PL9643 for the treatment of dry eye disease or DED. RTTNews

07:05AM EST Palatin Technologies Announces Results From Phase 2 Study Of PL9643 In Patients With Dry Eye Disease; Statistical Significance For The Primary Endpoints Was Not Reached In The Overall Enrolled Population Benzinga

07:02AM EST Palatin Reports Positive Results From Phase 2 Study Of PL9643 In Patients With Dry Eye Disease RTTNews

07:01AM EST Palatin Technologies Announces Positive Results From its Phase 2 Study of PR Newswire

Nov 17, 2020

07:34AM EST Palatin Technologies Q1 Net Loss $3.9 Mln Or $0.02/Shr Vs Loss Of $4.5 Mln Or $0.02/Shr Last Year RTTNews

07:31AM EST Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2021 Results and PR Newswire

07:31AM EST Palatin Technologies Q1 Adj. EPS $(0.02) Beats $(0.03) Estimate, Sales $(288.56K) Miss $1.00M Estimate Benzinga

04:07AM EST Earnings Scheduled For November 17, 2020 Benzinga

Nov 12, 2020

07:31AM EST Palatin Technologies, Inc. to Report First Quarter, Fiscal Year 2021 Results; PR Newswire

Sep 28, 2020

07:57AM EDT Palatin Technologies Inc. (PTN) reported that its net loss for the fourth quarter ended June 30, 2020 was $7.30 million or $0.03 per share, compared to net income of $52.2 million or $0.23 per share in the previous year. It was due to the recognition of license and contract revenue pursuant to its license agreement with AMAG of $60.3 million for the quarter ended June 30, 2019. RTTNews

07:32AM EDT Palatin Technologies Q4 Loss/Shr $0.03 Vs EPS $0.23 Last Year RTTNews

07:32AM EDT Palatin Technologies Q4 EPS $(0.03) Misses $(0.02) Estimate Benzinga

07:30AM EDT Palatin Technologies, Inc. Announces Fourth Quarter and Fiscal Year 2020 PR Newswire

04:00AM EDT Earnings Scheduled For September 28, 2020 Benzinga

Sep 24, 2020

04:00PM EDT Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year End 2020 PR Newswire

Sep 10, 2020

05:48PM EDT Palatin Technologies To Present At The H.C. Wainwright & Co. 22nd Annual Global PR Newswire

Aug 13, 2020

04:13PM EDT Palatin Technologies Participates In Canaccord Genuity's 40th Annual Growth PR Newswire

Aug 5, 2020

07:42AM EDT Palatin Technologies, Inc. Announces Completion Of Enrollment Of Phase 2 Study With PL9643 For The Treatment Of Dry Eye Disease Benzinga

07:33AM EDT Palatin Technologie Completes Enrollment Of Phase 2 Study With PL9643 For Dry Eye Disease RTTNews

07:31AM EDT Palatin Technologies, Inc. Announces Completion of Enrollment of Phase 2 Study PR Newswire

Jul 27, 2020

07:45AM EDT Palatin Technologies Inc. (PTN) said it has mutually terminated the January 2017 license agreement which granted AMAG Pharmaceuticals exclusive North American rights to market Vyleesi, the first and only on demand treatment for pre-menopausal women suffering from acquired, generalized, hypoactive sexual desire disorder (HSDD), a condition affecting one in ten premenopausal women. RTTNews

07:03AM EDT Palatin Technologies Terminates its Agreement Granting AMAG Pharma Exclusive North American Reights to Market Vyleesi Benzinga

07:02AM EDT Palatin Technologies Mutually Terminates License Agreement With AMAG Pharmaceuticals For Vyleesi RTTNews

07:01AM EDT Palatin Technologies Announces Mutual Termination of License Agreement with PR Newswire

Share